Corbus Pharmaceuticals entered into a two-year employment agreement with Dr. Leonardo Viana Nicacio as Chief Medical Officer, effective August 3, 2026. The deal includes a $545,000 base salary, a target bonus of up to 40% of salary, and $2.1 million in equity inducement awards split between stock options and restricted stock units. The agreement also outlines severance terms, non-compete, and non-solicitation clauses.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CORBUS PHARMACEUTICALS HOLDI (CRBP)?

Major stakeholders currently include Cormorant Asset Management, LP ($22.0M), Orbimed Advisors LLC ($16.3M), Aberdeen Group plc ($12.4M). Based on the latest 13F filings, there are a total of 105 tracked investment funds and institutions maintaining positions in CRBP.

What is the overall institutional sentiment toward CRBP recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $15.4M, driven by 53 managers accumulating shares while 36 reduced their exposure.

Which institutions have been selling or reducing their CRBP positions?

In the latest period, 22 funds trimmed their holdings, and 14 managers completely exited their positions. The aggregate reported sell value was $36.1M.

Are there any notable investors adding CRBP to their portfolios?

Yes, buying activity remains notable. 20 institutions opened new positions in {ticker}, and 33 existing holders added to their shares. The total reported buy value for the quarter amounted to $57.1M.